Candriam Equities L Biotechnology Class C USD CapRekisteröidy nähdäksesi ratingit |
Rahaston kehitys | 29.02.2024 |
1000 euron arvon kehitys (EUR) | Tarkempi kaavio |
Rahasto | 9,4 | 4,7 | 5,0 | 3,5 | 5,0 | |
+/- Luokka | -9,9 | 7,8 | 17,8 | 2,5 | -0,6 | |
+/- Ind. | -16,4 | -2,2 | 8,0 | -6,4 | -1,4 | |
Luokka: Sektori bioteknologia osakkeet | ||||||
Luokan vertailuindeksi: Morningstar Gbl Biotechnolo... |
Yleiskatsaus | ||
Osuuden arvo 27.03.2024 | USD 852,90 | |
1 pv muutos | 1,32% | |
Morningstar rahastoluokka™ | Sektori bioteknologia osakkeet | |
ISIN | LU0108459040 | |
Rahaston koko (Mil) 27.03.2024 | USD 1623,37 | |
Rahastosarjan koko (Mil) 27.03.2024 | USD 350,38 | |
Merkintä (Max) | - | |
Juoksevat kulut 01.03.2024 | 1,98% |
Morningstarin analyysi |
Analyst Report | 18.03.2024 Jeffrey Schumacher, Director Morningstar, Inc |
An expanding and highly qualified team led by one of the industry’s most seasoned investors in the field, combined with a proven process give this fund an edge. The fund’s cheapest share classes receive a Morningstar Analyst Rating of Silver,... | |
Paina tästä lukeaksesi analyysin |
Morningstarin pilarit | |
---|---|
Tiimi | 24 |
Taustayhtiö | 23 |
Prosessi | 24 |
Tuotto | |
Hinta |
Sijoituspolitiikka: Candriam Equities L Biotechnology Class C USD Cap |
The objective of the sub-fund is to use discretionary management to benefit from the performance of the market in global equities of companies from the biotechnology sector, and to outperform the benchmark. This sub-fund may be appropriate for investors who wish to achieve this objective over a long investment holding period and who are aware of, understand and are able to bear the specific risks of the sub-fund as set out below and defined in the section entitled Risk factors in the Prospectus. |
Tuotto | |||||||||||||
|
Hallinnointi | ||
Salkunhoitaja Salkunhoitajana alkaen | ||
Rudi Van den Eynde 06.04.2000 | ||
Perustamispäivä 06.04.2000 |
Mainos |
Luokan vertailuindeksi | |
Rahaston vertailuindeksi | Morningstar-vertailuindeksi |
NASDAQ Biotechnology TR USD | Morningstar Gbl Biotechnology NR USD |
Kohdemarkkina | ||||||||||||||||||||
|
Rahastosalkun sisältö Candriam Equities L Biotechnology Class C USD Cap | 31.01.2024 |
|
|
5 suurinta sijoitusta | Sektori | % |
Vertex Pharmaceuticals Inc | Terveydenhuolto | 7,10 |
Amgen Inc | Terveydenhuolto | 6,84 |
Regeneron Pharmaceuticals Inc | Terveydenhuolto | 6,50 |
Gilead Sciences Inc | Terveydenhuolto | 6,24 |
AstraZeneca PLC | Terveydenhuolto | 3,49 |
Nousu Lasku Uusi salkussa | ||
Candriam Equities L Biotechnology Class C USD Cap |